Levi & Korsinsky notifies investors that it has commenced an investigation into Phreesia, Inc. (NYSE: PHR) concerning potential violations of the federal securities laws.
On December 8, 2025, CFO Balaji Gandhi told investors on the Q3 2026 earnings call: "For fiscal year 2027, we expect revenue to be in the range of $545 million to $559 million." Gandhi also stated that the recently acquired AccessOne would "contribute approximately 6.5% of our fiscal 2027 total revenue outlook." On March 30, 2026, the Company issued its Q4 2026 earnings release and reduced FY 2027 revenue guidance to $510-$520 million -- a reduction of $35 million to $49 million from the prior range. The Company attributed the revision to weaker pharmaceutical-marketing commitments and shorter visibility in its Network Solutions segment. Neither risk factor had been referenced in the December 8, 2025 earnings call, where management described "progress" in the selling season for network solutions. The stock fell 21-28% on the revised outlook.
If you suffered a loss on your Phreesia, Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Tell us the stocks you own using SnapTrade, and we will keep you informed about class action litigation related to your stocks.
We monitor critical case developments that may affect the price of your shares and your possible monetary recovery.
SnapTrade only shares the tickers you own and your transaction history — not your account numbers. Using SnapTrade and participating in our monitoring service is free and does not create an attorney-client relationship or obligation on your part.
Don’t miss out on possible monetary recovery — link your brokerage account with SnapTrade.